Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 4, 2006, Pages 1064-1071

  Valicenti, Richard K ^a   DeSilvio, Michelle ^b   Hanks, Gerald E ^c   Porter, Arthur ^d   Brereton, Harmar ^e   Rosenthal, Seth A ^f   Shipley, William U ^g   Sandler, Howard M ^h  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d DETROIT MEDICAL CENTER   (United States)

^e Mercy Hospital   (United States)

^f Radiological Associates of Sacramento Medical Group Inc   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Mortality; Prostate cancer; Prostate specific antigen doubling time; Surrogate endpoint

Indexed keywords

HAZARDS; MATHEMATICAL MODELS; MEASUREMENT THEORY; PATIENT TREATMENT; RADIOTHERAPY; TESTING;

MORTALITY; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME; SURROGATE ENDPOINTS;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BIOASSAY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RANDOMIZATION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRACTICE GUIDELINES; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 33750348034     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.06.017     Document Type: Article

References (17)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. D'Amico A., Moul J., Carroll P., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
3. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 629-633
4. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1596
5. Albertsen P., Hanley J., Penson D., et al. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171 (2001) 2221-2225
6. Prentice R.L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8 (1989) 431-440
7. Hanks G., Pajak T., Porter A., et al. Phase III Trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
8. American Society for Therapeutic Radiology and Oncology, and American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement; guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
9. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
10. Cox D.R. Regression models and life-tables. J Royal Statist Soc Series B 34 (1972) 187-202
11. Hanks G.E., Hanlon A., Lee W.R., et al. Pretreatment prostate-specific antigen doubling times: Clinical utility of the predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549
12. D'Amico A., Renshaw A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
13. Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004) 2260-2264
14. Freedland S., Humphreys E., Mangold L., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
15. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer specific survival following radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2005) 4567-4573
16. Hanlon A.L., Diratzoian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297
17. Petrylak D.P., Tangen C.M., Hussain H.M., et al. Docetaxel and estramustine compared with mitoxantrone and predisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520